SecBot SecBot
8-K ·Filed Nov 5, 2026

TNDM

TANDEM DIABETES CARE INC
BULLISH
Impact 6/10
Horizondays Processed11d 10h ago SEC0001438133-26-000143
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The strong Q3 beat and reaffirmed guidance suggest the pay-as-you-go pharmacy channel is scaling effectively. Monitor the Q4 earnings call for 2027 guidance and further pharmacy formulary expansion updates.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$16.91
T+0 close · Nov 5, 2026 · via day close
Latest settled
+18.69%
T+5 · $20.07 · next T+20 in 20d
Vs SPY
+16.09%
α at T+5
Latest observation
+9.91%
T+6 · FF3 residual α
  1. T+0 · Nov 6 $16.91entry
  2. T+1 · 8d ago +7.45%α +5.08% · $18.17
  3. T+5 · 4d ago +18.69%α +16.09% · $20.07
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Tandem Diabetes Care reported Q3 2026 sales of $283.7M (+14% YoY), above the $265.8M consensus, and a GAAP net loss per share of -$0.10, beating the consensus estimate of -$0.24. The company reaffirmed its full-year 2026 guidance for sales of $1.065B-$1.085B and gross margin of 56%-57%. Operating loss narrowed to -$2.4M from -$22.9M a year ago, and adjusted EBITDA improved to $18.0M (6% of sales) from $2.8M (1% of sales).

Key Financial Metrics

EPS
−$0.10
est −$0.24 · +58.3%
Revenue
$283.7M
est $265.8M · +6.7% · +13.8% YoY
Rating
beat
Guidance
$1.065B-$1.085B
maintained
Free Cash Flow
-$5.5M
Gross Margin
57%

Key Facts

  • Q3 2026 sales of $283.7M, +14% YoY vs $249.3M, above $265.8M consensus
  • GAAP net loss per share -$0.10 vs consensus -$0.24
  • Gross margin 57%, up 270 bps YoY from 54%
  • Operating loss improved to -$2.4M (-1% of sales) from -$22.9M (-9% of sales)
  • Adjusted EBITDA $18.0M (6% of sales) vs $2.8M (1% of sales) a year ago
  • Full-year 2026 guidance reaffirmed: sales $1.065B-$1.085B, gross margin 56%-57%
  • U.S. pump shipments nearly 23,000, international nearly 11,000
  • Pharmacy channel reached 15% of U.S. sales; formulary coverage ~50% of U.S. lives

Financial Impact

Q3 sales beat consensus by $17.9M (6.7%); EPS beat by $0.14 (58.3%); operating loss narrowed by $20.5M YoY

revenueepsgross marginoperating lossadjusted EBITDA

Segment Breakdown

SegmentRevenueGrowth
United States$191.0M+9.0%
International$92.6M+26.0%

Risk Factors

  • Company still GAAP net loss-making (-$7.1M in Q3, -$48.6M YTD)
  • Free cash flow negative at -$5.5M in Q3 and -$39.4M YTD
  • Convertible senior notes of $603.4M represent significant leverage
  • U.S. pump sales declined 2% YoY in Q3, offset by supplies growth

Market Snapshot

Exchange
Nasdaq
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
60% bullish (30 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001438133-26-000143
Document: tndm-20261105.htm0001438133-26-000143
Document: 0001438133-26-000143-index-headers.html0001438133-26-000143
Document: 0001438133-26-000143-index.html0001438133-26-000143
Document: 0001438133-26-000143.txt0001438133-26-000143
8-K Data (Synthetic)0001438133-26-000143

Track record

9 reports on TNDM

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $18.50 Now $18.48 +0.11% settles Nov 18
  2. Nov 16, 2026today SC 13G Neutral 4/10 Entry $20.00 Now $18.48 −7.60% settles Nov 17
  3. Nov 13, 20263d ago 8-K Bullish 5/10 Entry $20.07 to $18.48 Now $18.48 −7.92% ▼ −7.92% −6.01% vs SPY
  4. Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $18.71 to $18.77 Now $18.48 −1.23% ▲ +0.32% −1.00% vs SPY
  5. Nov 5, 202611d ago 8-K Bullish 6/10 Viewing Entry $16.91 to $18.17 Now $18.48 +9.28% ▲ +7.45% +5.08% vs SPY
  6. Oct 27, 202620d ago 144 Neutral 2/10 Entry $19.68 to $19.79 Now $18.48 −6.10% ▲ +0.56% +0.94% vs SPY
  7. Jun 11, 202622w ago Institutional Cluster Mixed 5/10 Entry $15.80 to $16.60 Now $18.48 +16.96% ▲ +5.06% +4.52% vs SPY
  8. May 15, 202626w ago 8-K Neutral 3/10 Entry $12.82 to $13.53 Now $18.48 +44.15% ▲ +5.54% +5.60% vs SPY
  9. Apr 7, 202631w ago DEFA14A Neutral 3/10 Entry $19.35 to $19.68 Now $18.48 −4.50% ▲ +1.71% +1.13% vs SPY
Showing 9 of 9

US Market Status

Market Closed · Opens in 6h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026